EBV-induced upregulation of CD55 reduces the efficacy of cetuximab treatment in nasopharyngeal carcinoma
Qian Zhu, Xiao-Bing Duan, Hao Hu, Rui You, Tian-Liang Xia, Tao Yu, Tong Xiang, Ming-Yuan Chen · 2024
Read EBV-induced upregulation of CD55 reduces the efficacy of cetuximab treatment in nasopharyngeal carcinoma by Qian Zhu, Xiao-Bing Duan, Hao Hu, Rui You, Tian-Liang Xia, Tao Yu, Tong Xiang, Ming-Yuan Chen (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11653747.txt.
Description
Qian Zhu and co-workers study why a cancer drug works less well in throat cancer linked to Epstein-Barr virus, in a 2024 paper. The drug cetuximab targets a growth receptor and helps patients live longer. Yet tumor levels of that receptor do not predict who responds.
The team found that infected cancer cells raise a protective protein called CD55. That protein mainly blocks one immune attack route, in which killer cells destroy antibody-tagged tumor cells. A viral protein drives the rise through a known signaling pathway. The authors suggest that drugs blocking CD55 could restore the treatment's effect, giving a clear next step to test.
Catalog record
| CREATOR | Qian Zhu, Xiao-Bing Duan, Hao Hu, Rui You, Tian-Liang Xia, Tao Yu, Tong Xiang, Ming-Yuan Chen |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |